CSIMarket
 
Tcr2 Therapeutics Inc   (TCRR)
Other Ticker:  
 
 
Price: $1.4800 $-0.10 -6.329%
Day's High: $1.63 Week Perf: -15.43 %
Day's Low: $ 1.48 30 Day Perf: -19.57 %
Volume (M): 3,913 52 Wk High: $ 2.04
Volume (M$): $ 5,792 52 Wk Avg: $1.68
Open: $1.58 52 Wk Low: $1.34



 Market Capitalization (Millions $) 58
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -163
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) 14

Tcr2 Therapeutics Inc
TCR2 Therapeutics Inc is a biotechnology company specializing in the development of T-cell immunotherapies to treat cancer. Their approach involves using T-cell receptors (TCRs) to enhance the body's immune response against cancer cells. TCR2's therapies are designed to target solid tumors and blood cancers by engineering T-cells to recognize and attack specific tumor antigens. The company is focused on developing next-generation, safe and effective treatments that harness the power of the immune system to eliminate cancer cells.


   Company Address: 100 Binney Street Cambridge 2142 MA
   Company Phone Number: 949-5200   Stock Exchange / Ticker: NASDAQ TCRR
   TCRR is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Tcr2 Therapeutics Inc

TCRR's Rising Expenses Threaten Long-Term Viability, Tcr2 Therapeutics Inc Reports Significant Q1 Shortfall

As the Biotechnology & Pharmaceuticals sector continues to be dominated by large companies, it can be easy to overlook the smaller players in the industry. However, recent reports from some of these lesser-known companies shed light on their financial performance and potential for growth in the future.
One of these companies is Tcr2 Therapeutics Inc, which recently reported an operating shortfall of $-41.507 million for the first quarter of 2023. This represents a significant increase from the $-29.203 million shortfall reported in the first quarter of 2022. The company is now working on implementing various financial plans in order to ensure the continuation of its services.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com